Glenmark Pharmaceuticals is currently trading at Rs. 2134.75, up by 7.60 points or 0.36% from its previous closing of Rs. 2127.15 on the BSE.

The scrip opened at Rs. 2127.15 and has touched a high and low of Rs. 2147.00 and Rs. 2119.20 respectively. So far 12702 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.

Last one week high and low of the scrip stood at Rs. 2147.00 and Rs. 2020.05 respectively. The current market cap of the company is Rs. 60108.77 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.33% and 14.02% respectively.

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is all set to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials. Glenmark’s Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Sodium Phosphates Injection USP, 45 mM P/15 mL (3 mM P/mL), of Hospira, Inc. [NDA 018892], with the 15 mM P/5 mL (3 mM P/mL) and 150 mM P/50 mL (3 mM P/mL) presentations expected to have the same therapeutic effect as that of the listed drug product upon which the FDA relied as the basis of safety and effectiveness. Glenmark will begin distribution in April 2026.

According to IQVIA sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials market achieved annual sales of approximately $66.8 million.

Glenmark’s Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials is only approved for the indication(s) listed in Glenmark’s approved label.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.